Some investors asked on the investor interaction platform: for so many years, the hospital business is still listed and injected, and the pharmaceutical manufacturing is basically those. It seems that it is not very successful to acquire a nursing home business. Therefore, we are curious about the sudden incentive of employees at the top of the company. Our minority shareholders are surprised? What did the top management of the company do for the listed company?
Jinling Pharmaceutical Company Limited(000919) (000919. SZ) said on the investor interaction platform on January 24 that the company’s main business is drug manufacturing and medical care services. Among them, medical and health care services mainly refer to professional medical services provided by Suqian hospital (acquired in 2003), Yizheng hospital (acquired in 2012) and anqing hospital (acquired in 2014), as well as health care services provided by welfare companies (acquired in 2018).
